These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21791636)

  • 1. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Working with NICE.
    Adams C
    J Fam Health Care; 2007; 17(4):113-4. PubMed ID: 17824208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing the National Institute for Health and Clinical Excellence.
    Jaques H
    Eur Heart J; 2012 Sep; 33(17):2111-2. PubMed ID: 23106069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence.
    Wonderling D; Sawyer L; Fenu E; Lovibond K; Laramée P
    Ann Intern Med; 2011 Jun; 154(11):758-65. PubMed ID: 21646559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10 years of NICE: still growing and still controversial.
    Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
    Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putting National Institute for Health and Clinical Excellence guidance into practice: a cost minimization model of a national roll-out of liquid based cytology in England.
    Stoykova B; Kuzmanov G; Dowie R
    Int J Technol Assess Health Care; 2008; 24(4):391-8. PubMed ID: 18828932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NHS and charitable funding for children and young people with cancer in England and Wales.
    Linck P; Tunnage B; Hughes DA; Edwards RT
    J Child Health Care; 2008 Jun; 12(2):156-68. PubMed ID: 18469299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.